AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 156 filers reported holding AGIOS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 1.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $24,809 | -5.6% | 1,002,403 | +8.0% | 0.08% | -6.2% |
| Q2 2023 | $26,288 | +11.5% | 928,259 | -9.6% | 0.08% | -1.2% |
| Q1 2023 | $23,581 | -17.3% | 1,026,587 | +1.1% | 0.08% | -19.6% |
| Q4 2022 | $28,526 | -99.9% | 1,015,879 | +9.8% | 0.10% | -1.0% |
| Q3 2022 | $26,171,000 | +31.9% | 925,430 | +3.4% | 0.10% | +35.5% |
| Q2 2022 | $19,841,000 | -28.8% | 894,958 | -6.6% | 0.08% | -21.6% |
| Q1 2022 | $27,885,000 | -1.4% | 957,930 | +11.3% | 0.10% | +3.2% |
| Q4 2021 | $28,279,000 | -23.4% | 860,343 | +7.5% | 0.09% | -31.4% |
| Q3 2021 | $36,939,000 | -16.7% | 800,414 | -0.6% | 0.14% | -13.3% |
| Q2 2021 | $44,356,000 | +8.4% | 804,860 | +1.6% | 0.16% | -6.5% |
| Q1 2021 | $40,907,000 | +31.8% | 792,152 | +10.6% | 0.17% | +18.2% |
| Q4 2020 | $31,028,000 | +116.1% | 716,078 | +74.6% | 0.14% | +74.4% |
| Q3 2020 | $14,358,000 | -23.2% | 410,222 | +17.3% | 0.08% | -34.9% |
| Q2 2020 | $18,702,000 | +25.6% | 349,708 | -16.7% | 0.13% | -0.8% |
| Q1 2020 | $14,887,000 | -32.4% | 419,598 | -9.1% | 0.13% | -15.9% |
| Q4 2019 | $22,037,000 | +91.2% | 461,502 | +29.7% | 0.15% | +69.7% |
| Q3 2019 | $11,528,000 | -26.7% | 355,790 | +12.9% | 0.09% | -30.5% |
| Q2 2019 | $15,719,000 | -17.4% | 315,127 | +11.6% | 0.13% | -19.5% |
| Q1 2019 | $19,041,000 | +120.5% | 282,345 | +48.1% | 0.16% | +98.8% |
| Q4 2018 | $8,636,000 | -55.3% | 190,649 | -23.9% | 0.08% | -45.9% |
| Q3 2018 | $19,313,000 | +13.6% | 250,423 | +24.1% | 0.15% | +4.2% |
| Q2 2018 | $16,997,000 | +23.9% | 201,792 | +20.3% | 0.14% | +22.4% |
| Q1 2018 | $13,714,000 | -4.9% | 167,691 | -33.5% | 0.12% | -5.7% |
| Q4 2017 | $14,416,000 | -15.7% | 252,160 | -1.5% | 0.12% | -15.2% |
| Q3 2017 | $17,094,000 | +61.6% | 256,086 | +24.5% | 0.14% | +54.3% |
| Q2 2017 | $10,580,000 | +13.3% | 205,641 | +28.5% | 0.09% | +9.3% |
| Q1 2017 | $9,342,000 | +69.7% | 159,970 | +21.2% | 0.09% | +62.3% |
| Q4 2016 | $5,506,000 | +2.5% | 131,945 | +29.7% | 0.05% | +15.2% |
| Q3 2016 | $5,372,000 | – | 101,707 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 354,650 | $18,314,000 | 7.19% |
| Casdin Capital, LLC | 2,165,000 | $111,801,000 | 3.33% |
| Rock Springs Capital Management LP | 2,543,600 | $131,352,000 | 2.87% |
| HealthCor Management, L.P. | 1,532,960 | $79,162,000 | 2.80% |
| Bellevue Group AG | 4,537,092 | $234,295,000 | 2.48% |
| Woodline Partners LP | 824,097 | $42,556,000 | 0.94% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,081,347 | $55,841,000 | 0.83% |
| Integral Health Asset Management, LLC | 43,000 | $2,221,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,119,566 | $57,814,000 | 0.43% |
| Virtus ETF Advisers LLC | 18,328 | $946,000 | 0.40% |